Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma

2004 ◽  
Vol 58 (3) ◽  
pp. 768-772 ◽  
Author(s):  
Ralf Wilkowski ◽  
Martin Thoma ◽  
Eckhart Dühmke ◽  
Horst Günter Rau ◽  
Volker Heinemann
Keyword(s):  
Pancreatic Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
R1 Resection ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma ◽  
Gemcitabine And Cisplatin

scholarly journals Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy

2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
Erkan Topkan ◽  
Huseyin Mertsoylu ◽  
Ahmet Kucuk ◽  
Ali Ayberk Besen ◽  
Ahmet Sezer ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Systemic Inflammation ◽  
Roc Curve ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Prognostic Significance ◽  
Inflammation Response ◽  
Response Index ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma

Background. We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT). Methods. Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT. The SIRI was defined as: SIRI=neutrophil×monocyte/lymphocyte counts. Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis. The primary endpoint was the interaction between the SIRI and OS results. Results. The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively. ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients (N=58) had significantly superior median PFS (13.8 versus 6.7 months; P<0.001) and OS (28.6 versus 12.6 months; P<0.001) lengths than SIRI ≥1.6 patients (N=96), respectively. Although the N0 (versus N1; P<0.05) and CA 19-9 ≤90 U/mL (versus >90 U/mL) appeared as the other significant associates of better OS and PFS in univariate analyses, yet the results of multivariate analyses confirmed the SIRI <1.6 as the independent indicator of superior OS and PFS (P<0.001 for each). Conclusion. Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT.

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma

2005 ◽  
Vol 76 (1) ◽  
pp. 48-53 ◽  
Author(s):  
Morten Hoyer ◽  
Henrik Roed ◽  
Lisa Sengelov ◽  
Anders Traberg ◽  
Lars Ohlhuis ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Phase Ii ◽  
Stereotactic Radiotherapy ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma

Radical resection after radiofrequency ablation of locally advanced pancreatic carcinoma

2013 ◽  
Vol 39 (9) ◽  
pp. S45
Author(s):  
A. Giardino ◽  
R. Girelli ◽  
I. Frigerio ◽  
P. Regi ◽  
F. Scopelliti ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Pancreatic Carcinoma ◽  
Locally Advanced ◽  
Radical Resection ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma

scholarly journals CA19-9 response and CT-imaging predict resectability of locally advanced pancreatic carcinoma following neoadjuvant chemotherapy

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S685
Author(s):  
E. van Veldhuisen ◽  
J.A. Vogel ◽  
O.R. Busch ◽  
J.W. Wilmink ◽  
K.P. van Lienden ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Pancreatic Carcinoma ◽  
Locally Advanced ◽  
Ct Imaging ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma
Sign in / Sign up

Export Citation Format

Share Document